Brain cell transplant trial aims to restore movement in Parkinson's

NCT ID NCT07080775

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage trial tests a single injection of lab-grown nerve cells into the brains of 12 people with Parkinson's disease. The cells are made from stem cells and designed to replace dopamine-producing neurons. The main goal is to check safety and tolerability over 28 days, not yet to prove it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

iPSC-derived dopaminergic neural progenitor cells

What this could lead to

If this works, it could point toward a new way to replace lost brain cells and improve motor function in Parkinson's disease.

What could go wrong

This is a very early Phase 1 safety trial with only 12 people. It may not show benefit, and brain injection carries risks like bleeding or infection.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSON'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beijing Tiantan Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100070, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••